Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03716102 · ClinicalTrials.gov registry record · NA

OPTIMIZE Sirolimus-Eluting Coronary Stent Systems Pharmacokinetics (PK) Study

A NA study of Acute Coronary Syndrome, sponsored by Svelte Medical Systems.

Active
Registry status
NA
Development phase
12
Enrollment target
2
Study locations

NCT03716102: Active NA study of Acute Coronary Syndrome, sponsored by Svelte Medical Systems.

NCT03716102 is a NA study of Acute Coronary Syndrome that is active but no longer recruiting, run by Svelte Medical Systems. The registered enrollment target is 12 participants, below the 2,722-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03716102, a NA study of Acute Coronary Syndrome, is active but no longer recruiting, sponsored by Svelte Medical Systems.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
12 participants
Enrollment target
2
Study locations

Study Summary

To evaluate the pharmacokinetic parameters of sirolimus release from the Svelte DES.

Conditions Studied

Interventions

  • DEVICE PCI with implantation with DES

Study Locations (2)

Arizona

  • Scottsdale Healthcare - Scottsdale

Michigan

  • Northern Michigan Hospital d.b.a McLaren Northern Michigan - Petoskey

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2018-11-21
Est. Completion 2021-07-15
Phase NA
Svelte Medical Systems

2 total trials

What the registry record for NCT03716102 still lists

NCT03716102 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 2,722-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 1 intervention - of which PCI with implantation with DES is the first listed.

NCT03716102 reports a single indexed study location in Arizona, Michigan.

Frequently Asked Questions

What is clinical trial NCT03716102 about?

NCT03716102 is a clinical study titled "OPTIMIZE Sirolimus-Eluting Coronary Stent Systems Pharmacokinetics (PK) Study". To evaluate the pharmacokinetic parameters of sirolimus release from the Svelte DES.

What is the current status of trial NCT03716102?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2018-11-21. Estimated completion is 2021-07-15.

What conditions does trial NCT03716102 study?

This clinical trial studies the following conditions: Acute Coronary Syndrome.

What interventions are being tested in trial NCT03716102?

The interventions under investigation include: PCI with implantation with DES (DEVICE).

Who is sponsoring clinical trial NCT03716102?

This trial is sponsored by Svelte Medical Systems, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03716102 being conducted?

This trial has 2 study locations across Arizona, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Coronary Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03716102's enrollment target sits among peer trials

12 40th of 40 higher than 1 of 40 other Acute Coronary Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Coronary Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03716102, the US trial registry maintained by the National Library of Medicine. NCT03716102 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.